Member Info for itsallamess

Imagine if we know about the steriods use before the last trial.. And then covid turned up. We would be the No. 1 mention for treating ARDS in covid paitents and they all would be on Traumakine now.

Any how this is where we are and soon enough we will see our IV interferon beta 1a recognized by the medical field and mainstream media

Good to see that this info is share price sensitive and deserved a RNS

https://nordiclifescience.org/nine-indian-hospitals-approved-to-join-the-global-solidarity-trial/

"The trial will evaluate four treatment protocols — Remdesivir, a combination of Lopinavir and Ritonavir, Hydroxychloroquine, and Lopinavir and Ritonavir with Interferon beta-1a"

Would make sense to pump their money back in...

This BOD have always been keen on buying shares in their own company!

"The AGM resolved that an annual remuneration of EUR 35,000 will be paid to the Board members, in addition to which an annual remuneration of EUR 35,000 will be paid to the Chair of the Board. In addition, a further annual remuneration of EUR 11,000 will be paid to the Chair of the Audit Committee, a further annual remuneration of EUR 9,000 will be paid to the Chair of the Remuneration Committee and a further annual remuneration of EUR 6,000 will be paid to the Chair of the Nomination Committee. In addition, a further annual remuneration of EUR 6,000 will be paid to the Audit Committee members, a further annual remuneration of EUR 5,000 will be paid to the Remuneration Committee members and a further annual remuneration of EUR 3,000 will be paid to the Nomination Committee members"

We closed at 359

16:27:58 19-May-2020 360.00 GBX 10,000 36,000.00
16:28:13 19-May-2020 359.64 GBX 10,000 35,964.00

These last 2 trades 72 grand have to be buys

As someone said recently, look at the trades, the small random sizes are PIs but the big buys that keep popping up are the big boys.

The last 2 today could well be the agm one off payments the BOD gets each year. 35k was it?

Let's see if we get a TR1 in the morning!

I reckon it's a typo. It's from 1 article and more to the point the who solidarity trials don't inxlude b1. It's interferon a1.

https://relief.unboundmedicine.com/relief/view/Coronavirus-Guidelines/2355044/all/Coronavirus_COVID_19_Outbreak___What's_New

? Drugs
? Interferon beta-1b, lopinavir–ritonavir, and ribavirin combination reported in an open label, randomized trial (NCT04276688) to be safe and superior to lopinavir–ritonavir alone in alleviating symptoms and shortening hosptial stay and viral shedding in patients with mild to moderate COVID-19.[10]

? Hydroxychloroquine (HCQ):
Observational study published in JAMA showed amongst 1,438 hospitalized COVID-19 patients those receiving HCQ, azithromycin, or both had no significant differences in mortality from those not receiving these drugs.[11]
Observational study published in NEJM showed HCQ not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death.

Remdesivir:
The Lancet reported on a randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov NCT04257656) at ten hospitals in Hubei, China that showed treatment with remdesivir was not associated with statistically significant clinical benefits. There was a non-significant trend towards reduction in time to clinical improvement in those with symptom duration of 10 days or less. Some authors have concluded that the study was underpowered to detect a statistical difference.
According to preliminary results of an NIH-sponsored clinical trial (ACTT; NCT04280705) remdesivir accelerated recovery from advanced COVID-19:[12

https://www.eanpages.org/2020/05/19/triple-combination-of-interferon-beta-1b-lopinavir-ritonavir-and-ribavirin-in-the-treatment-of-patients-admitted-to-hospital-with-covid-19-an-open-label-randomised-phase-2-trial/

"No patients died during the study. The authors concluded that early triple antiviral therapy was safe and superior to lopinavir–ritonavir alone in shortening the duration of viral shedding in patients with mild to moderate COVID-19"

Of course it's possible that remdesivir deosnt work on it's own but when taking with interferon beta 1a there are good results showing that Traumakine is the winner

https://www.linkedin.com/jobs/view/1865962884/

One possibility is if the results of the who solidarity trial show a diference between remdesivir working along with interferon beta 1a in particular Traumakine IV formulation will Gilead want to partner with faron?

https://m.economictimes.com/news/international/world-news/who-sees-potentially-positive-data-on-covid-19-treatments/articleshow/75694942.cms

Wonder if Traumakine is one of them :)

On the agm presentation under next steps for Traumakine, one step is submit peer review articles

This is one of such articles

Next step after this is manufacturing... expect news to drop on this soon

https://link.springer.com/article/10.1007/s00134-020-06086-3

Sounds like recruiting to deal with the roll out of clevegen to multiple test sites

.

370

Thanks Dan

Very interesting, may give us a little I sight on how many trails of Traumakine have been done and any early results

Another nice buy 09:05:42 / 365.00 /. 5,000 / £18,250.00

It's true CB
Very interested in this tweet

https://twitter.com/KariTikkinen/status/1261955252884049922?s=19

08:00:19 365.00 9,000 32,850.00

Nice buy first thing